Daiichi Sankyo's investments in cancer drugs are taking shape

From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany

22-Nov-2024 - Bavaria's Minister President Dr. Markus Söder has marked the start of construction of a building at the production and development site of the Japanese pharmaceutical company Daiichi Sankyo in Pfaffenhofen (Ilm) with a symbolic ground-breaking ceremony, where so-called antibody drug conjugates ...

Predicting the mode of action of new anti-cancer drugs with AI

Acceleration of the development of new cancer drugs

22-Nov-2024 - Plants, fungi and bacteria produce a variety of active substances that alter cell metabolism, sometimes to the point of cell death. This makes them promising candidates for new drugs against cancer and other diseases. Although a diverse range of bioactives exists, the further development of new ...

Impressive results against autoimmune disease

Severe systemic lupus no longer detectable after cancer medication treatment

06-Sep-2024 - The team at Charité – Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old was wheelchair-bound due to the autoimmune ...

Key to Improving Cancer Treatments Discovered

Discovery Paves the Way for the Development of Precise Inhibitors

07-Jun-2024 - Some cancer drugs cause severe side effects because they are not working accurately enough. A team at the University of Würzburg led by biochemist Caroline Kisker has now discovered why. The small protein ubiquitin is involved in almost every cellular process in our body: it orchestrates the ...

New AI platform designs tomorrow’s cancer drugs

“A few years ago, AI was a dirty word in the pharmaceutical industry, but now the trend is definitely the opposite...”

08-May-2024 - Scientists at UC San Diego have developed a machine learning algorithm to simulate the time-consuming chemistry involved in the earliest phases of drug discovery, which could significantly streamline the process and open doors for never-before-seen treatments. Identifying candidate drugs for ...

Game changer in fighting cancer: BioCopy expands corporate portfolio with acquisition of start-up Perspix Biotech

"BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint"

11-Apr-2024 - BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and ...

Click, click, boom—150 new molecules within days instead of months

A new study calls accelerated SuFEx click chemistry “a robust platform for drug discovery”

08-Apr-2024 - Cold Spring Harbor Laboratory (CSHL) chemists have created a new collection of molecular compounds and begun testing them as potential leads in the search for new drugs. Among these molecules, they found several that show promise for development as antibiotics and cancer therapies. Sounds like a ...

A new path to active ingredient diversity

26-Mar-2024 - Many important drugs, such as antibiotics and cancer drugs, are derived from natural substances from bacteria. The bacterial enzymes that produce these active ingredients are considered ideal tools for synthetic biology due to their modular design. By researching protein evolution, a team led by ...

Cancer drug works against viruses

01-Sep-2023 - TWINCORE researchers describe a mechanism that inhibits virus replication and protects cells from damage. Interestingly, a drug that has already been approved could prove useful in combating various viruses. AIDS, the flu, COVID-19 - time and again, viral infections overtake entire regions of ...

Fighting tumours down to the last cancer cell

Researchers at PSI have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer

06-Jul-2023 - The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the Paul Scherrer Institute, the University Hospital Basel and ETH Zurich is receiving two million Swiss francs in funding for this project. In Switzerland, about 7100 men are diagnosed with ...